Onconetix (ONCO) Competitors

$0.52 -0.13 (-19.62%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 0.00 (-0.58%)

As of 07:58 PM Eastern

ONCO vs. MEHA, ATXI, CNSP, SNOA, and ZVSA

Should you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Functional Brands (MEHA), Avenue Therapeutics (ATXI), CNS Pharmaceuticals (CNSP), Sonoma Pharmaceuticals (SNOA), and ZyVersa Therapeutics (ZVSA). These companies are all part of the "pharmaceutical products" industry.

How does Onconetix compare to Functional Brands?

Functional Brands (NASDAQ:MEHA) and Onconetix (NASDAQ:ONCO) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

: 23.9% of Onconetix shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Functional Brands has a net margin of 0.00% compared to Onconetix's net margin of -1,717.50%. Onconetix's return on equity of 8.24% beat Functional Brands' return on equity.
Company Net Margins Return on Equity Return on Assets
Functional Brands N/A N/A N/A
Onconetix -1,717.50% 8.24% 2.90%
: In the previous week, Onconetix had 1 more articles in the media than Functional Brands. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for Functional Brands. Functional Brands' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.
Company Overall Sentiment
Functional Brands Neutral
Onconetix Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Functional Brands
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Onconetix
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Functional Brands has higher revenue and earnings than Onconetix. Onconetix is trading at a lower price-to-earnings ratio than Functional Brands, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Functional Brands $6.61M 0.33 $760K $0.04 2.50
Onconetix $810K 0.42 -$14.03M -$216.73 N/A

Company	Net Margins	Return on Equity	Return on Assets
Functional Brands	N/A	N/A	N/A
Onconetix	-1,717.50%	8.24%	2.90%

Company	Overall Sentiment
Functional Brands	Neutral
Onconetix	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Functional Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Functional Brands	$6.61M	0.33	$760K	$0.04	2.50
Onconetix	$810K	0.42	-$14.03M	-$216.73	N/A

Summary

Onconetix beats Functional Brands on 6 of the 11 factors compared between the two stocks.

How does Onconetix compare to Avenue Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

: Avenue Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,717.50%. Onconetix's return on equity of 8.24% beat Avenue Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Avenue Therapeutics N/A -471.57% -296.50%
Onconetix -1,717.50% 8.24% 2.90%
: In the previous week, Onconetix had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for Avenue Therapeutics. Avenue Therapeutics' average media sentiment score of 0.00 equaled Onconetix'saverage media sentiment score.
Company Overall Sentiment
Avenue Therapeutics Neutral
Onconetix Neutral
: Avenue Therapeutics has higher earnings, but lower revenue than Onconetix. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avenue Therapeutics N/A N/A -$10.38M -$0.94 N/A
Onconetix $810K 0.42 -$14.03M -$216.73 N/A
: 17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Onconetix
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Avenue Therapeutics has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Onconetix has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Onconetix	-1,717.50%	8.24%	2.90%

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Onconetix	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.94	N/A
Onconetix	$810K	0.42	-$14.03M	-$216.73	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Onconetix beats Avenue Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Onconetix compare to CNS Pharmaceuticals?

Onconetix (NASDAQ:ONCO) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

: CNS Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -1,717.50%. Onconetix's return on equity of 8.24% beat CNS Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Onconetix -1,717.50% 8.24% 2.90%
CNS Pharmaceuticals N/A -164.56% -130.05%
: In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 1 mentions for Onconetix. CNS Pharmaceuticals' average media sentiment score of 0.97 beat Onconetix's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Onconetix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CNS Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Onconetix has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Onconetix $810K 0.42 -$14.03M -$216.73 N/A
CNS Pharmaceuticals N/A N/A -$15.85M -$41.30 N/A
: 23.9% of Onconetix shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 0.3% of Onconetix shares are held by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 179.72%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Onconetix.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconetix
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
CNS Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: Onconetix has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.62, suggesting that its stock price is 162% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,717.50%	8.24%	2.90%
CNS Pharmaceuticals	N/A	-164.56%	-130.05%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CNS Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	0.42	-$14.03M	-$216.73	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$41.30	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Onconetix beats CNS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Onconetix compare to Sonoma Pharmaceuticals?

Onconetix (NASDAQ:ONCO) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

: In the previous week, Onconetix had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Onconetix and 0 mentions for Sonoma Pharmaceuticals. Onconetix's average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Onconetix Neutral
Sonoma Pharmaceuticals Neutral
: Sonoma Pharmaceuticals has a net margin of -19.04% compared to Onconetix's net margin of -1,717.50%. Onconetix's return on equity of 8.24% beat Sonoma Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Onconetix -1,717.50% 8.24% 2.90%
Sonoma Pharmaceuticals -19.04% -42.56% -11.97%
: Sonoma Pharmaceuticals has higher revenue and earnings than Onconetix. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Onconetix $810K 0.42 -$14.03M -$216.73 N/A
Sonoma Pharmaceuticals $14.29M 0.15 -$3.46M -$2.04 N/A
: Onconetix has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconetix
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Sonoma Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 23.9% of Onconetix shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 0.3% of Onconetix shares are held by company insiders. Comparatively, 24.6% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Overall Sentiment
Onconetix	Neutral
Sonoma Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,717.50%	8.24%	2.90%
Sonoma Pharmaceuticals	-19.04%	-42.56%	-11.97%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	0.42	-$14.03M	-$216.73	N/A
Sonoma Pharmaceuticals	$14.29M	0.15	-$3.46M	-$2.04	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Onconetix beats Sonoma Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Onconetix compare to ZyVersa Therapeutics?

Onconetix (NASDAQ:ONCO) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

: In the previous week, Onconetix and Onconetix both had 1 articles in the media. Onconetix's average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Onconetix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ZyVersa Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: ZyVersa Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,717.50%. Onconetix's return on equity of 8.24% beat ZyVersa Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Onconetix -1,717.50% 8.24% 2.90%
ZyVersa Therapeutics N/A -109.54% -43.95%
: ZyVersa Therapeutics has lower revenue, but higher earnings than Onconetix. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Onconetix $810K 0.42 -$14.03M -$216.73 N/A
ZyVersa Therapeutics N/A N/A -$9.41M -$1.34 N/A
: Onconetix has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconetix
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
ZyVersa Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 23.9% of Onconetix shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.3% of Onconetix shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ZyVersa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,717.50%	8.24%	2.90%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	0.42	-$14.03M	-$216.73	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$1.34	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Onconetix beats ZyVersa Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCO vs. The Competition

Export

Metric	Onconetix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$420K	$3.40B	$6.25B	$11.77B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	0.00	22.62	24.91	23.23
Price / Sales	0.42	280.78	504.56	75.49
Price / Cash	N/A	125.06	43.30	53.90
Price / Book	0.01	7.05	9.67	6.69
Net Income	-$14.03M	$23.62M	$3.55B	$332.64M
7 Day Performance	-32.31%	3.67%	1.70%	2.01%
1 Month Performance	-65.79%	7.17%	5.62%	9.19%
1 Year Performance	-98.26%	67.04%	34.42%	39.59%

Onconetix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCO Onconetix	1.0456 of 5 stars	$0.52 -19.6%	N/A	N/A	$420K	$810K	N/A	12	Upcoming Earnings Analyst Upgrade Gap Down
MEHA Functional Brands	N/A	$0.09 -14.2%	N/A	N/A	$1.85M	$6.61M	2.22	33
ATXI Avenue Therapeutics	N/A	$0.55 flat	N/A	N/A	$1.81M	N/A	0.03	4	Gap Down
CNSP CNS Pharmaceuticals	2.2472 of 5 stars	$2.22 -1.8%	$20.00 +800.9%	N/A	$1.80M	N/A	N/A	5	News Coverage Positive News Gap Up
SNOA Sonoma Pharmaceuticals	0.7086 of 5 stars	$1.03 -0.8%	N/A	N/A	$1.79M	$17.72M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCO) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Onconetix (ONCO) Competitors

ONCO vs. MEHA, ATXI, CNSP, SNOA, and ZVSA

How does Onconetix compare to Functional Brands?

Summary

How does Onconetix compare to Avenue Therapeutics?

Summary

How does Onconetix compare to CNS Pharmaceuticals?

Summary

How does Onconetix compare to Sonoma Pharmaceuticals?

Summary

How does Onconetix compare to ZyVersa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Onconetix (ONCO) Competitors

ONCO vs. MEHA, ATXI, CNSP, SNOA, and ZVSA

How does Onconetix compare to Functional Brands?

Summary

How does Onconetix compare to Avenue Therapeutics?

Summary

How does Onconetix compare to CNS Pharmaceuticals?

Summary

How does Onconetix compare to Sonoma Pharmaceuticals?

Summary

How does Onconetix compare to ZyVersa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools